Identifying tumor cell-released extracellular vesicles as biomarkers for breast cancer diagnosis by a three-dimensional hydrogel-based electrochemical immunosensor
-
Published:2023-12-07
Issue:1
Volume:21
Page:
-
ISSN:1477-3155
-
Container-title:Journal of Nanobiotechnology
-
language:en
-
Short-container-title:J Nanobiotechnol
Author:
Zhang Yue,Pan Deng,Ning Zhenqiang,Huang Fang,Wei Yiting,Zhang Mingming,Zhang Yuanjian,Wang Li-xin,Shen Yanfei
Abstract
AbstractTumor cell-released LC3+ extracellular vesicles (LC3+ EVs) participate in immunosuppression during autophagy and contribute to the occurrence and development of breast cancer. In view of the strong association between the LC3+ EVs and breast cancer, developing an effective strategy for the quantitative detection of LC3+ EVs levels with high sensitivity to identify LC3+ EVs as new biomarkers for accurate diagnosis of breast cancer is crucial, but yet not been reported. Herein, an ultrasensitive electrochemical immunosensor is presented for the quantitative determination of LC3+ EVs using a three-dimensional graphene oxide hydrogel-methylene blue composite as a redox probe, showing a low detection limit and a wide linear range. With this immunosensor, the expression levels of LC3+ EVs in various practical sample groups including different cancer cell lines, the peripheral blood of tumor-bearing mice before and after immunotherapy, and the peripheral blood from breast cancer patients with different subtypes and stages were clearly distinguished. This study demonstrated that LC3+ EVs were superior as biomarkers for the accurate diagnosis of breast cancer compared to traditional biomarkers, particularly for cancer subtype discrimination. This work would provide a new noninvasive detection tool for the early diagnosis and prognosis assessment of breast cancer in clinics.
Funder
High-level Innovation and Entrepreneurship Talent Introduction Plan of Jiangsu Province NSFC Cultivation Project of Nanjing Medical University National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Subject
Pharmaceutical Science,Applied Microbiology and Biotechnology,Biomedical Engineering,Molecular Medicine,Medicine (miscellaneous),Bioengineering
Reference41 articles.
1. Seung E, Xing Z, Wu L, Rao E, Cortez-Retamozo V, Ospina B, Chen L, Beil C, Song Z, Zhang B, et al. A trispecific antibody targeting HER2 and T cells inhibits Breast cancer growth via CD4 cells. Nature. 2022;603:328–34. 2. Yang YK, Chen C, Zuo QZ, Lu HQ, Salman S, Lyu YJ, Huang YT, Wicks E, Jackson W, Datan E, et al. NARF is a hypoxia-induced coactivator for OCT4- mediated Breast cancer stem cell specification. Sci Adv. 2022;8:eabo5000. 3. Zhao W, Hu X, Li W, Li R, Chen J, Zhou L, Qiang S, Wu W, Shi S, Dong C. M2-Like TAMs function reversal contributes to Breast Cancer eradication by Combination Dual Immune Checkpoint Blockade and Photothermal Therapy. Small. 2021;17:e2007051. 4. Chunai Gong XY, You B, Wu Y, Wang R, Han L, Wang Y, Gao S, Yuan Y. Macrophage-cancer hybrid membrane-coated nanoparticles for targeting lung Metastasis in Breast cancer therapy. J Nanobiotechnol. 2020;18:92. 5. Key Cancer Data and Key Figures on IARC. : 2020–2021 [https://www.iarc.who.int/biennial-report-2020-2021web/].
|
|